Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy

Overview

Journal Front Pharmacol

Date 2021 Feb 1

PMID 33519471

Citations 18

Authors

Shota Yamamoto

Nobuaki Egashira

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe adverse effect observed in most patients treated with neurotoxic anti-cancer drugs. Currently, there are no therapeutic options available for the prevention of CIPN. Furthermore, few drugs are recommended for the treatment of existing neuropathies because the mechanisms of CIPN remain unclear. Each chemotherapeutic drug induces neuropathy by distinct mechanisms, and thus we need to understand the characteristics of CIPN specific to individual drugs. Here, we review the known pathogenic mechanisms of oxaliplatin- and paclitaxel-induced CIPN, highlighting recent findings. Cancer chemotherapy is performed in a planned manner; therefore, preventive strategies can be planned for CIPN. Drug repositioning studies, which identify the unexpected actions of already approved drugs, have increased in recent years. We have also focused on drug repositioning studies, especially for prevention, because they should be rapidly translated to patients suffering from CIPN.

Citing Articles

Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment.

Mattar M, Umutoni F, Hassan M, Wamburu M, Turner R, Patton J Life (Basel). 2024; 14(8).

PMID: 39202733 PMC: 11355765. DOI: 10.3390/life14080991.

KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats.

Ippolito M, Hayduk S, Kinney W, Brenneman D, Ward S J Pharmacol Exp Ther. 2024; 391(2):231-240.

PMID: 39134424 PMC: 11493436. DOI: 10.1124/jpet.124.002190.

Exploration for Blood Biomarkers of Human Long Non-coding RNAs Predicting Oxaliplatin-Induced Chronic Neuropathy Through iPS Cell-Derived Sensory Neuron Analysis.

Sakai A, Yamada T, Maruyama M, Ueda K, Miyasaka T, Yoshida H Mol Neurobiol. 2024; 61(9):7168-7180.

PMID: 38374315 DOI: 10.1007/s12035-024-04017-7.

Microtubule stabilising peptides: new paradigm towards management of neuronal disorders.

Bhargava S, Kulkarni R, Dewangan B, Kulkarni N, Jiaswar C, Kumar K RSC Med Chem. 2023; 14(11):2192-2205.

PMID: 37974959 PMC: 10650357. DOI: 10.1039/d3md00012e.

3', 4'-dihydroxyflavone ameliorates paclitaxel model of peripheral neuropathy in mice by modulating K channel, adenosine (A) and GABA (α subunit) receptors.

Ramasamy K, Shanmugasundaram J, Subramanian V, Manoharan R, Kathirvelu P, Vijayaraghavan R Bioinformation. 2023; 19(6):754-763.

PMID: 37885774 PMC: 10598353. DOI: 10.6026/97320630019754.

References

Xu Z, Zhang L, Liu T, Park J, Berta T, Yang R . Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med. 2010; 16(5):592-7, 1p following 597. PMC: 2866054. DOI: 10.1038/nm.2123. View

Li D, Huang Z, Ling Y, Wei J, Cui Y, Zhang X . Up-regulation of CX3CL1 via Nuclear Factor-κB-dependent Histone Acetylation Is Involved in Paclitaxel-induced Peripheral Neuropathy. Anesthesiology. 2014; 122(5):1142-51. DOI: 10.1097/ALN.0000000000000560. View

Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V . Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011; 3(5):266-78. PMC: 3377073. DOI: 10.1002/emmm.201100134. View

Kerckhove N, Busserolles J, Stanbury T, Pereira B, Plence V, Bonnetain F . Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. BMJ Open. 2019; 9(6):e027770. PMC: 6561607. DOI: 10.1136/bmjopen-2018-027770. View

Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T . Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep. 2017; 7(1):5947. PMC: 5519765. DOI: 10.1038/s41598-017-05784-1. View

Schwartzentruber J, Foskolou S, Kilpinen H, Rodrigues J, Alasoo K, Knights A . Molecular and functional variation in iPSC-derived sensory neurons. Nat Genet. 2017; 50(1):54-61. PMC: 5742539. DOI: 10.1038/s41588-017-0005-8. View

Kawashiri T, Egashira N, Kurobe K, Tsutsumi K, Yamashita Y, Ushio S . L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain. 2012; 8:7. PMC: 3285049. DOI: 10.1186/1744-8069-8-7. View

Bessaguet F, Danigo A, Bouchenaki H, Duchesne M, Magy L, Richard L . Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia. Pain. 2018; 159(12):2538-2546. DOI: 10.1097/j.pain.0000000000001361. View

Wozniak K, Vornov J, Wu Y, Liu Y, Carozzi V, Rodriguez-Menendez V . Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. Cancer Res. 2017; 78(3):817-829. PMC: 5811354. DOI: 10.1158/0008-5472.CAN-17-1467. View

10.

Yamamoto S, Egashira N, Tsuda M, Masuda S . Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats. J Pharmacol Sci. 2018; 138(3):214-217. DOI: 10.1016/j.jphs.2018.10.006. View

11.

LoCoco P, Risinger A, Smith H, Chavera T, Berg K, Clarke W . Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. Elife. 2017; 6. PMC: 5701795. DOI: 10.7554/eLife.29626. View

12.

Nishida K, Takeuchi K, Hosoda A, Sugano S, Morisaki E, Ohishi A . Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. Life Sci. 2018; 207:516-524. DOI: 10.1016/j.lfs.2018.07.006. View

13.

Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T . Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019; 140(3):291-294. DOI: 10.1016/j.jphs.2019.05.009. View

14.

Wainger B, Buttermore E, Oliveira J, Mellin C, Lee S, Saber W . Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts. Nat Neurosci. 2014; 18(1):17-24. PMC: 4429606. DOI: 10.1038/nn.3886. View

15.

Wing C, Komatsu M, Delaney S, Krause M, Wheeler H, Dolan M . Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res. 2017; 22:79-88. PMC: 5737666. DOI: 10.1016/j.scr.2017.06.006. View

16.

Nishida T, Tsubota M, Kawaishi Y, Yamanishi H, Kamitani N, Sekiguchi F . Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016; 365:48-58. DOI: 10.1016/j.tox.2016.07.016. View

17.

Boehmerle W, Zhang K, Sivula M, Heidrich F, Lee Y, Jordt S . Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A. 2007; 104(26):11103-8. PMC: 1904151. DOI: 10.1073/pnas.0701546104. View

18.

Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N . Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain. 2011; 152(7):1621-1631. DOI: 10.1016/j.pain.2011.02.051. View

19.

Tsutsumi K, Yamashita Y, Ushio S, Kawashiri T, Kaname T, Fujita S . Oxaliplatin induces hypomyelination and reduced neuregulin 1 expression in the rat sciatic nerve. Neurosci Res. 2014; 80:86-90. DOI: 10.1016/j.neures.2014.02.004. View

20.

Zheng H, Xiao W, Bennett G . Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011; 232(2):154-61. PMC: 3202047. DOI: 10.1016/j.expneurol.2011.08.016. View